Clinical Study for Huazhuo Tongmai Decoction in the Treatment of Primary Hyperlipidemia Complicated with Carotid Atherosclerosis
- Conditions
- Primary hyperlipidemia with carotid atherosclerosis
- Registration Number
- ITMCTR1900002533
- Lead Sponsor
- Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1) Accord with the diagnostic criteria of hyperlipidemia: accord with any of the following: TC (> 6.22 mmol/L); 2.26 mmol/L (= TG (= 5.63 mmol/L);
2) LDL-C (> 4.14 mmol/L);
3) Accord with the diagnostic criteria of carotid atherosclerosis;
4) TCM syndrome differentiation belongs to phlegm stagnation syndrome;
5) Aged between 30 and 70 years;
6) The research program is approved and signed by the ethical committees of clinical research. The patient knows and voluntarily signs the informed consent;
7) Those who have stopped taking lipid-lowering drugs for more than 4 weeks or met the above criteria at the end of the introduction period.
1) Pregnant or lactating women, allergic constitution and drug allergy;
2) Patients who have suffered from acute myocardial infarction, cerebrovascular accident, severe trauma or major surgery within six months;
3) Secondary hyperlipidemia;
4) Hyperlipidemia and homozygous hypercholesterolemia caused by drugs (phenothiazines, beta-blockers adrenocorticosteroids and some contraceptives, etc.);
5) Patients who are using heparin, thyroxine or other drugs that affect lipid metabolism, and those who have taken other lipid-lowering measures in the past two weeks;
6) Psychiatric patients with severe primary diseases such as liver, kidney and hematopoietic system.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TG;TC;LDL-C;
- Secondary Outcome Measures
Name Time Method Integral of TCM Syndrome;HDL-C;Crouse;